[1]邵毅,周琼.糖尿病视网膜病变诊治规范——2018年美国眼科学会临床指南解读[J].眼科新进展,2019,39(6):501-506.[doi:10.13389/j.cnki.rao.2019.0115]
　SHAO Yi,ZHOU Qiong.Interpretation of clinical guidelines for diabe-tic retinopathy of the American Academy of Ophthalmology 2018[J].Recent Advances in Ophthalmology,2019,39(6):501-506.[doi:10.13389/j.cnki.rao.2019.0115]
点击复制

糖尿病视网膜病变诊治规范——2018年美国眼科学会临床指南解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年6期
页码:
501-506
栏目:
述评
出版日期:
2019-06-05

文章信息/Info

Title:
Interpretation of clinical guidelines for diabe-tic retinopathy of the American Academy of Ophthalmology 2018
作者:
邵毅; 周琼
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi; ZHOU Qiong
Department of Ophthalmology，the First Affi-liated Hospital of Nanchang University，Nanchang 330006，Jiangxi Province，China
关键词:
糖尿病视网膜病变; 分类; 诊断; 治疗; 指南
Keywords:
diabetic retinopathy; classification; diagnosis; treatment; guidelines
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2019.0115
文献标志码:
A
摘要:
美国眼科协会出台了2018年糖尿病视网膜病变临床指南，对糖尿病视网膜病变的定义、发病人群、分类、检测方法与治疗等做了详细介绍。本文将对该指南及最新有关治疗进行全面解读。
Abstract:
American Academy of Ophthalmology recently issued 2018 Diabetic Retinopathy Preferred Practice Pattern，which gives a detailed introduction to the definition,patient population,classification,detection methods and treatment of diabetic retinopathy.This article will give a comprehensive interpretation of the guidelines and the latest treatment.

参考文献/References:

［1］　LADDHA A P，KULKARNI Y A.Tannins and vascular complications of diabetes：an update［J］.Phytomedicine，2018，56：229-245.
［2］　KLEIN B E.Overview of epidemiologic studies of diabetic retinopathy［J］.Ophthalmic Epidemiol，2007，14(4)：179-183.
［3］　UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes：UKPDS 38［J］.BMJ，1998，317(7160)：703-713.
［4］　SNOW V，WEISS K B，MOTTUR-PILSON C.The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus［J］.Ann Intern Med，2003，138(7)：587-592.
［5］　LOPES-VIRELLA M F，BAKER N L，HUNT K J，LYONS T J，JENKINS A J，VIRELLA G.High concentrations of AGE-LDL and oxidized LDL incirculating immune complexes are associated with progression of retinopathy in type 1 diabetes［J］.Diabetes Care，2012，35(6)：1333-1340.
［6］　AMERICAN D A.Standards of medical care in diabetes--2013［J］.Diabetes Care，2013，36 Suppl 1：S11-66.
［7］　KLEIN R，KLEIN B E，MOSS S E，DAVIS M D，DEMETS D L.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.III.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years［J］.Arch Ophthalmol，1984，102(4)：527-532.
［8］　VARMA R，TORRES M，PENA F，KLEIN R，AZEN S P.Prevalence of diabetic retinopathy in adult Latinos：the Los Angeles Latino eye study［J］.Ophthalmology，2004，111(7)：1298-1306.
［9］　HIRAI F E，KNUDTSON M D，KLEIN B E，KLEIN R.Clinically significant macular edema and survival in type 1 and type 2 diabetes［J］.Am J Ophthalmol，2008，145(4)：700-706.
［10］　Diabetes Prevention Program Research Group.The prevalence of retinopathy in impaired glucosetolerance and recent-onset diabetes in the Diabetes Prevention Program［J］.Diabet Med，2007，24(2)：137-144.
［11］　KILPATRICK E S，RIGBY A S，ATKIN S L，FRIER B M.Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the diabetes control and complications trial database［J］.Diabet Med，2012，29(9)：1195-1198.
［12］　DAVIS M D，FISHER M R，GANGNON R E，BARTON F，AIELLO L M，CHEW E Y，et al.Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss：early treatment diabetic retinopathy study report number 18［J］.Invest Ophthalmol Vis Sci，1998，39(2)：233-252.
［13］　Diabetes Control and Complications Trial Research Group.Effect of pregnancy on microvascularcomplications in the diabetes control and complications trial［J］.Diabetes Care，2000，23(8)：1084-1091.
［14］　American Academy of Ophthalmology Preferred Practice Patterns Committee.Preferred practice pattern?Guidelines.Comprehensive adult medical eye evaluation［EB/OL］.San francisco，CA：American academy of ophthalmology；2010［2019-01-20］.http：//www.aao.org/ppp.
［15］　Diabetes Control and Complications Trial Research Group.The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus：the Diabetes Control and Complications Trial［J］.Arch Ophthalmol，1995，113(1)：36-51.
［16］　KLEIN R，KLEIN B E，MOSS S E，DAVIS M D，DEMETS D L.Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy［J］.JAMA，1988，260(19)：2864-2871.
［17］　Diabetic Retinopathy Clinical Research Network.A randomi-zed trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema［J］.Ophthalmology，2008，115(9)：1447-1459.
［18］　CHEW E Y，KLEIN M L，FERRIS F L，REMALEY N A，MURPHY R P，CHANTRY K，et al.Association of elevated serum lipid levels with retinal hardexudate in diabetic retinopathy：Early Treatment Diabetic Retinopathy Study (ETDRS) report 22［J］.Arch Ophthalmol，1996，114(9)：1079-1084.
［19］　KAISER P K，RIEMANN C D，SEARS J E，LEWIS H.Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction［J］.Am J Ophthalmol，2001，131(1)：44-49.
［20］　LIU H T，TANG J，DU Y P，SAADANE A，TONADE D，SAMUELS I，et al.Photoreceptor cells influence retinal vascular degeneration in mouse models of retinal degeneration and diabetes［J］.Invest Ophthalmol Vis Sci，2016，57：4272-4281.
［21］　YANNUZZI L A，ROHRER K T，TINDEL L J，SOBEL R S，COSTANZA M A，SHIELDS W，et al.Fluorescein angiography complication survey［J］.Ophthalmology，1986，93(5)：611-617.
［22］　SUNNESS J S.The pregnant woman’s eye［J］.Surv Ophthalmol，1988，32(4)：219-238.
［23］　AREVALO J F.Intravitreal bevacizumab in diabetic retinopathy.Recommendations from the Pan-American Collaborative Retina Study Group (PACORES)：The 2016 Knobloch Lecture［J］.Asia Pac J Ophthalmol (Phila)，2018，7(1)：36-39.
［24］　CAI S，YANG Q，LI X，ZHANG Y.The efficacy and safety of aflibercept and conbercept in diabetic macular edema［J］.Drug Des Devel Ther，2018，12：3471-3483.
［25］　ZHAO Y，SINGH R P.The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy［J］.Drugs Context，2018，7：212532.
［26］　ELMAN M J，QIN H，AIELLO L P，BECK R W，BRESSLER N M，FERRIS F L，et al.Diabetic Retinopathy Clinical Research Network.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment：three-year randomized trial results［J］.Ophthalmology，2012，119(11)：2312-2318.
［27］　Diabetic Retinopathy Clinical Research Network.Aflibercept，bevacizumab，or ranibizumab for diabetic macular edema［J］.N Engl J Med，2015，372(13)：1193-1203.
［28］　WELLS J A，GLASSMAN A R，AYALA A R，JAMPOL L M，BRESSLER N M，BRESSLER S B，et al.Aflibercept，bevacizumab，or ranibizumab for diabetic macular edema：two-year results from a comparative effectiveness randomized clinical trial［J］.Ophthalmology，2016，123(6)：1351-1359.
［29］　PARKE D W，COLEMAN A L，RICH W L，LUM F.Choosing Wisely：five ideas that physicians and patients can discuss［J］.Ophthalmology，2013，120(3)：443-444.
［30］　BANDELLO F，BRANCATO R，MENCHINI U，VIRGILI G，LANZETTA P，FERRARI E，et al.Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy［J］.Sem Ophthalmol，2001，16(1)：12-18.
［31］　Centers for Disease Control and Prevention (CDC).Prevalence of diagnosed diabetes among American Indians/Alaskan Natives--United States 1996［J］.MMWR Morb Mortal Wkly Rep，1998，47(42)：901-904.
［32］　LEWIS H，SCHACHAT A P，HAIMANN M H，HALLER J A，QUINLAN P，VON FRICKEN M A，et al.Choroidal neovascularization after laser photocoagulation for diabetic macular edema［J］.Ophthalmology，1990，97(4)：503-510.
［33］　ELIKER H，ERDA G ˇ I BULUT A， AHIN .Comparison of efficacy and side effects of multispot lasers and conventional lasers for diabetic retinopathy treatment［J］.Turk J Ophthalmol，2017，47：34-41.
［34］　LU Z，WEN W，YAN G，LAN J，XIE L.The efficacy and safety of current treatments in diabetic macular edema：A Systematic Review and Network Meta-Analysis［J］.PLoS One，2016，11(7)：e0159553.
［35］　WHITCUP S M，CIDLOWSKI J A，CSAKY K G，AMBATI J.Pharmacology of corticosteroids for diabetic macular edema［J］.Invest Ophthalmol Vis Sci，2018，59(1)：1-12.
［36］　Diabetic Retinopathy Clinical Research Network.Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema［J］.Arch Ophthalmol，2009，127(3)：245-251.
［37］　DO D V，NGUYEN Q D，KHWAJA A A，CHANNA R，SEPAH Y J，SOPHIE R，et al.READ-2 Study Group.Ranibizumab for edema of the macula in diabetes study：3-year outcomes and the need for prolonged frequent treatment［J］.JAMA Ophthalmol，2013，131(2)：139-145.
［38］　DENG L，JIA J，YAO J，XU Z.Stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 improves diabetic retinopathy［J］.Biosci Biotechnol Biochem，2019，［Epub ahead of print］.
［39］　OMORI K，NAGATA N，KURATA K，FUKUSHIMA Y，SEKIHACHI E，FUJII N，et al.Inhibition of stromal cell-derived factor-1α/CXCR4 signaling restores the blood-retina barrier in pericyte-deficient mouse retinas［J］.JCI Insight，2018，3(23)：e120706.
［40］　PARK H J，LEE W Y，KIM J H，PARK C，SONG H.Expression patterns and role of SDF-1/CXCR4 axis in boar spermatogonial stem cells［J］.Theriogenology，2018，113：221-228.
［41］　LI W，WEBSTER K A，LEBLANC M E，TIAN H.Secretogranin III：a diabetic retinopathy-selective angiogenic factor［J］.Cell Mol Life Sci，2018，75：635-647.
［42］　LEBLANC M E，WANG W W，JI Y L，TIAN H，LIU D，ZHANG X，et al.Secretogranin III as a novel target for the therapy of choroidal neovascularization［J］.Exp Eye Res，2019，181：120-126.
［43］　LEBLANC M E，WANG W W，CHEN X P，CABEROY N B，GUO F，SHEN C，et al.Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy［J］.J Exp Med，2017，214：1029-1047.
［44］　YOSHIDA S，NAKAMA T，ISHIKAWA K，NAKAO S，SONODA K H，ISHIBASHI T.Periostin in vitreoretinal diseases［J］.Cell Mol Life Sci，2017，74：4329-4337.
［45］　NAKAMA T，YOSHIDA S，ISHIKAWA K，KUBO Y，KOBAYASHI Y，ZHOU Y，et al.Therapeutic effect of novel single-stranded RNAi agent targeting periostin in eyes with retinal neovascularization［J］.Mol Ther Nucleic Acids，2017，6：279-289.
［46］　BERKOWITZ BA，BISSIG D，ROBERTS R.MRI of rod cell compartment-specific function in disease and treatment in vivo［J］.Prog Retin Eye Res，2016，51：90-106.
［47］　ARDEN G B，JYOTHI S，HOGG C H，LEE YF，SIVAPRASAD S.Regression of early diabetic macular oedema is associated with prevention of dark adaptation［J］.Eye，2011，25(12)：1546.
［48］　REN X J，BU S C，ZHANG X M，JIANG Y，TAN L，ZHANG H，et al.Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy［J］.Eye (Lond)，2019，［Epub ahead of print］.
［49］　ZHANG X，WU C，ZHOU LJ，DAI RP.Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections［J］.Sci Rep，2018，8：3972.
［50］　MAO J B，WU H F，CHEN Y Q，ZHAO S X，TAO J W，ZHANG Y，et al.Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy［J］.Int J Ophthalmol，2018，11：1217-1221.
［51］　VAN BERGEN T，JONCKX B，HOLLANDERS K，SIJNAVE D，VAN DE VELDE S，VANDEWALLE E，et al.Inhibition of placental growth factor improves surgical outcome of glaucoma surgery［J］.J Cell Mol Med，2013，17(12)：1632-1643.
［52］　SADDALA M S，LENNIKOV A，GRAB D J，LIU GS，TANG S，HUANG H.Proteomics reveals ablation of PlGF increases antioxidant and neuroprotective proteins in the diabetic mouse retina［J］.Sci Rep，2018，8：16728.
［53］　Early Treatment Diabetic Retinopathy Study Research Group.Focal photocoagulation treatment of diabetic macular edema.Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline：ETDRS report number 19［J］.Arch Ophthalmol，1995，113(9)：1144-1155.
［54］　ELMAN M J，BRESSLER N M，QIN H，BECK R W，FERRIS F L，FRIEDMAN S M，et al.Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema［J］.Ophthalmology，2011，118(4)：609-614.
［55］　FERRIS F.Early photocoagulation in patients with either type I or type II diabetes［J］.Trans Am Ophthalmol Soc，1996，94：505-537.
［56］　Diabetic Retinopathy Study Research Group.Four risk factors for severe visual loss in diabetic retinopathy：the third report from the Diabetic Retinopathy Study［J］.Arch Ophthalmol，1979，97(4)：654-655.
［57］　Early Treatment Diabetic Retinopathy Study Research Group.Techniques for scatter and local photocoagulation treatment of diabetic retinopathy：Early Treatment Diabetic Retinopathy Study report number 3［J］.Int Ophthalmol Clin，1987，27(4)：254-264.
［58］　OLSEN T W.Anti-VEGF pharmacotherapy as an alternative to panretinal laser photocoagulation for proliferative diabetic retinopathy［J］.JAMA，2015，314(20)：2135-2136.
［59］　Diabetic Retinopathy Vitrectomy Study Research Group.Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision：results of a randomized trial--Diabetic Retinopathy Vitrectomy Study report 3［J］.Ophthalmology，1988，95(10)：1307-1320.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81660158、81460092、81400372）；江西省自然科学基金重大项目（编号：2016ACB21017）；江西省青年科学基金（编号：20151BAB215016、20161BAB215198）；江西省重点研发项目（编号：20151BBG70223、20181BBG70004）；江西省教育厅重点项目（编号：GJJ160020）；江西省学位与研究生教育教学改革研究项目（编号：JXYJG-2018-013）；江西省基层卫生适宜技术“星火推广计划”项目（编号：20088003）；江西省卫计委科技计划面上项目（编号：20175116）；江西省卫计委中医药科技计划项目（编号：2018A060）
更新日期/Last Update: 2019-06-05